ECX — Epigenomics AG Cashflow Statement
0.000.00%
Last trade - 00:00
- €1.41m
- -€1.82m
- €0.49m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -12.7 | -17 | -11.7 | -2.43 | -12 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.943 | 3.25 | 0.689 | -1.12 | -0.043 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.09 | -0.245 | 0.894 | -1.02 | -0.706 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -10.4 | -13.5 | -9.57 | -4.15 | -12 |
Capital Expenditures | -0.106 | -0.122 | -0.021 | -0.035 | -1.36 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.83 | 0.169 | 0.024 | 0.996 | -0.335 |
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0.724 | 0.047 | 0.003 | 0.961 | -1.7 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 13.3 | 7.12 | 2.98 | 21.6 | -0.359 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 3.66 | -6.33 | -6.59 | 19.5 | -12.9 |